References
- Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692–6.
- Ricata AA. Bisphosphonate therapy. Am J Med Sci 1997; 313: 17–22.
- Patel S. Current and potential future drug treatments for osteoporosis Ann Rheum Dis 1996; 55: 700–14.
- Watts NB. Treatment of osteoporosis with bisphospho-nates. Rheum Dis Clin N Am 1994; 20: 714–34.
- Singer FR, Minoofar PN. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metabol 1995; 6: 259–88.
- Lando M, Hoover LA, Finerman G. Stabilization of hearing loss in Paget's disease with calcitonin and etidronate. Arch Otolaryngol Head Neck Surg 1988; 114: 891–4.
- Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 1991; 42: 919–44.
- Chung JVV, Yoon TH. Different production of inter-leukin- 1, interleukin-lp and interleukin-8 from cholesteatoma and normal epithelium. Acta Otolaryn-gol (Stockh) 1998; 118: 386–91.
- Cochran DL, Rouse CA. The effect of conditioned medium from connective tissue fibroblasts and epithe-lium on calcium release from mouse calvarial organ culture. Arch Oral Biol 1993; 38: 61–5.
- Richardson AC, Tinling SP, Chole RA. Risedronate activity in the fetal and neonatal mouse. Otolaryngol Head Neck Surg 1993; 109: 623–33.
- Kurihara A, Toshima M, Yuasa R, et al. Bone destruc-tion mechanisms in chronic otitis media with cholesteatoma: specific production by cholesteatoma tissue in culture of bone-resorbing activity attributable to interleukin-1 alpha. Ann Otol Rhinol Laryngol 1991; 100: 989–98.
- Ahn JM, Huang CC, Abramson M. Localization of interleukin-1 in human cholesteatoma. Am J Otolaryn-gol 1990; 11: 71–7.
- Schilling V, Negri B, Bujia J, et al. Possible role of interleukin-lot and interleukin-lp in the pathogenesis of cholesteatoma of the middle ear. Am J Otol 1992; 13: 350–5.
- Kim CS, Lee CH, Chung JVV, et al. Interleukin-lcx, interleukin-lp and interleukin-8 gene expression in hu-man aural cholesteatomas. Acta Otolaryngol (Stockh) 1996; 116: 302–6.
- Kakiuchi H, Kinoshita K, Katoh Y, et al. Interleukin-1 of cholesteatomatous keratinocytes. Ann Otol Rhinol Laryngol 1992; 101: 32–8.
- Patlas A, Yaffe P, Kimyagrav A, Golomb G, Ornoy A. Effects of continuous or cyclic administration of pamidronate on the skeleton in intact and oophorec-tomized young rats. Acta Anat (Basel) 1997; 159: 42–7.
- Nishikawa M, Akatsu T, Katayama Y, et al. Bisphos-phonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18: 9–14.
- Adachi K, Chole RA. Inhibition of osteoclast recruit-ment at a local site by 1-hydroxyethylidene-1, 1-bispho-sphonate (HEBP). Ann Otol Rhinol Laryngol 1990; 99: 738–41.
- Abramson M, Huang CC. Localization of collagenase in human middle ear cholesteatoma. Laryngoscope 1977; 87: 771–91.
- Chole RA. Cellular and subcellular events of bone resorption in human and experimental cholesteatoma: The role of osteoclasts. Laryngoscope 1984; 94: 76–95.
- Chole RA. Osteoclasts in chronic otitis media, cholesteatoma, and otosclerosis. Ann Otol Rhinol Laryngol 1988; 97: 661–6.